SGLT2 Inhibitors: Basic Training Quiz

The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.


The mechanism underlying the ability of empagliflozin to reduce measures of visceral adiposity may be a redistribution of fat to less vulnerable body areas.

The patient is new to you, he's got type 2 DM and has a lot of meds on board. There's danger in this mix. Read the history and see if you spot the problem.

After sleeve gastrectomy, obese patients with type 2 DM who have less severe disease do better than those who have more advanced disease. Surgery should be encouraged sooner rather than later.

Some of the reasons cited for the observed cost efficiencies: better achievement of A1C and composite quality-of-care goals and fewer treatment failures.

Diabetes and cardiac medications are reduced significantly in obese patients who undergo weight-loss surgery, and so are their costs.

In patients with A1c poorly controlled on metformin, dual add-on therapy with saxagliptin plus dapagliflozin brought more to A1c goals than either drug added alone.

Until now, the USPSTF has recommended against screening asymptomatic adults for diabetes. A recent draft recommendation shifts focus and suggests intermittent screening for certain high risk adults.


Subscribe to Diabetes on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.